KEI Intervention at WIPO’s SCP 20 on Patents and Health
Intervention of India at EB134 expressing solidarity with the Republic of South Africa in light of Pharmagate
During heated discussions on the topic of access to essential medicines at the 134th session of the World Health Organization’s Executive Board, India delivered the following statement on Thursday, 23 January 2014 expressing solidarity with the Republic of South Africa in light of the Pharmagate exposé.
SCP20: Opening statement of the European Union at WIPO’s Standing Committee on the Law of Patents, 27 January 2014
On 27 January 2014, Greece, on behalf of the European Union, delivered this opening statement at the 20th session of WIPO Standing Committee on the Law of Patents (SCP). The EU’s priorities for WIPO’s patent committee include quality of patents (including opposition systems), work sharing and confidentiality of communication between client and their patent advisors.
With respect to limitations and exceptions to patent rights, the EU said,
Intervention of the South Centre at EB134 expressing solidarity with the Republic of South Africa (English translation)
This is the English translation of the intervention delivered by the South Centre on Thursday, 23 January 2014 at the 134th session of the World Health Organization’s Executive Board expressing solidarity with the Government of the Republic of South Africa following the Pharmagate exposé.
Thank you, Madam President, for giving us the floor.
HAI and Medicus Mundi statements at WHO EB on CEWG demonstration projects
Three NGOs, Medicus Mundi International, HAI and MSF, each read statements during the EB discussions on the CEWG demonstration projects. The statements were limited to 300 words, and NGOs were required to provide the text 24 hours before the agenda item, and obtain WHO approval of the content. KEI worked with HAI on its statement, and the Peoples Health Movement worked with MMI on its statement. The text of the HAI and MMI statements follow:
Health Action International (HAI) statement to EB 134 On agenda item 9.3, follow up to CEWG on financing and coordination
Industry use of WHO Model List of Essential Medicines as defense against patent abuses
The following are some quotes by countries, companies, academics and other actors stating, suggesting or implying claiming that drugs not on the WHO Model List of Essential Medicines (WHO EML) should not be subject to a compulsory license.
Bayer. Political Principles.
http://www.bayer.com/en/innovation-requires-investment.aspx
Political Principles.
Innovation requires investment.
Good ideas must be worthwhile.EB134: Statement of South Africa on Access to Essential Medicines (in the wake of Pharmagate)
On Thursday, 23 January 2014, Malebona Precious Matsoso (Director General of the South African National Department of Health) delivered the the following intervention at the 134th session of the World Health Organization’s Executive Board under agenda item 9.7 on Access to essential medicines in response to the recent Pharmagate imbroglio.
Intervention of the South Centre at EB134 expressing solidarity with the Republic of South Africa
On Thursday, 23 January 2014, the South Centre delivered the following statement at the 134th session of the World Health Organization’s Executive Board under agenda item 9.7, access to essential medicines, expressing solidarity with the Government of the Republic of South Africa following the Pharmagate exposé.
GRACIAS SENORA PRESIDENTA POR DARNOS LA PALABRA.Blogs and Press coverage of Pharma/Medicine device industry lobbying on South Africa patent reform (pharmagate)
Boseley, Sarah. 17 January 2014. “South African pharma firms accused of planning to delay patents law reform.” The Guardian. http://www.theguardian.com/world/2014/jan/17/south-african-pharma-accused-delay-patents-law-reform
De Wet, Phillip. 17 January 2014. “Motsoaledi: Big pharma’s ‘satanic’ plot is genocide.” Mail & Guardian. http://mg.co.za/article/2014-01-16-motsoaledi-big-pharmas-satanic-plot-is-genocide/
Bayer CEO Marijn Dekkers explains: Nexavar cancer drug is for “western patients who can afford it.”
Bayer CEO Marijn Dekkers called the Nexavar compulsory license “essentially theft.” [UPDATE: The latest blog and transcript of Bayer CEO Marijn Dekkers’ full quote on the Indian compulsory license of Nexavar at the December Financial Times event is now available.]
